MarketMoodz
GSK — GSK plc
Is GSK overbought or oversold? Here is the current MarketMoodz read.
GSK plc (GSK) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of July 5, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $53.66. The rating moved from Neutral to Overbought on July 3, 2026 and has changed 28 times in the last 90 days.
- Public ratingOverbought (as of July 5, 2026)
- Last close$53.66
- Rating changesRating changed 28 times in the last 90 days
- Last changeMoved from Neutral to Overbought on July 3, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - General
Latest MarketMoodz coverage
- GSK, Spero Win FDA OK for First Oral Carbapenem for cUTIs2026-06-17
- Biotech IPO Window Reopens as Big Pharma Steps Up M&A2026-06-16
- GSK Eyes Nuvalent Buyout at $9–10B to Bulk Up Oncology2026-06-09
- Biotech M&A Hits $106B YTD, Poised to Rival 2019 Peak2026-06-04
- GSK and Sino Biopharmaceutical Strike Exclusive China Pact for Bepirovirsen2026-05-11
See today's live rating, score and targets
Members see the live hourly rating for GSK — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.